InsomniaPhase 3NCT00856973
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 73 sites in United States.
Trial summary
A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Insomnia, Attention Deficit Hyperactivity Disorder
- What is being tested?
- eszopiclone
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 486 participants
- Where
- 73 sitesUnited States
- Study dates
- May 2009to Jul 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Subject is male or female 6 to 17 years of age, inclusive, at the time of consent.
- Subject must have a diagnosis of ADHD as defined by DSM-IV criteria
- Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation, (wake time after sleep onset >45 minutes) despite adequate age appropriate time and opportunity for sleep.
- Subject's Baseline PSG must reveal either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake after sleep onset (WASO).
- Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
- Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time
Show all 10Show fewer
- Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.(Female subjects ≥8 years of age must have a negative serum pregnancy test)
- Subject must be in general good health
- Subject must be able to swallow tablets.
- If subject is currently taking medication for ADHD, they must be on a stable dose and regimen for a minimum of 1 month prior to the time of consent
Who cannot join
- Subject with weight <10th percentile for age and gender
- Subject has any clinically significant or unstable medical illness/abnormality or chronic disease.
- Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder or any history of psychosis.
- Subject has periodic limb movement >5 times per hour, as demonstrated on Baseline PSG.
- Subject has sleep disordered breathing, as demonstrated on Baseline PSG.
- Subject has another primary sleep disorder, a secondary sleep disorder, or any other known or suspected medical or psychiatric condition that has affected or may affect sleep
Show all 14Show fewer
- Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones more than once during the study.
- Subject has organic brain disease, or a history of febrile seizures.
- Subject is, in the opinion of the investigator, at suicidal or homicidal risk.
- Female subject who is pregnant or lactating or planning to become pregnant.
- Subject has taken any psychotropic medication without an appropriate washout period (≥5 half-lives) prior to randomization.
- Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
- Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.
- Subject has a history of alcohol or substance abuse within 3 months of study participation.
Trial locations and contacts
73 sites in 1 country.
73 sites in 1 country
United States73 sites
Neuro Trials Research, Inc.
Atlanta, Georgia, 30342
Sleep Disorders Center of Georgia
Atlanta, Georgia, 30342
Northwest Clinical Research Center
Bellevue, Washington, 98007
Sleep Disorders Center of Alabama
Birmingham, Alabama, 35213
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan, 48302
AV Institute, Inc.
Carson, California, 90746
Metropolitan Neuro Behavioral Institute
Chandler, Arizona, 85226
Carolina Clinical Trials Inc.
Charleston, South Carolina, 29405
Tristate Sleep Disorders Center
Cincinnati, Ohio, 45246
Delta Waves, INC
Colorado Springs, Colorado, 80918
Clinical Innovations, Inc.
Costa Mesa, California, 92626
InSite Clinical Research LLC
DeSoto, Texas, 75115
Dothan Behavioral Medicine Clinic
Dothan, Alabama, 36303
Mountain West Clinical Trials
Eagle, Idaho, 83616
Synergy Clinical Research Center
Farmingdale, New York, 11735
Avastra Clinical Trials
Fountain Valley, California, 92708
Sarkis Clinical Trials
Gainesville, Florida, 32607
MD & Associates, Inc.
Garfield Heights, Ohio, 44125
Clinical Insights
Glen Burnie, Maryland, 21061
Behavioral Research Specialists, LLC
Glendale, California, 91204
Mid-Michigan Sleep Center
Grand Blanc, Michigan, 48439
Cyn3rgy Research
Gresham, Oregon, 97030
MD Clinical
Hallandale, Florida, 33009
Clinical Research Center of Nevada
Henderson, Nevada, 89015
Alexian Brothers Center for Psychiatric Research
Hoffman Estates, Illinois, 60169
Claghorn-Lesem Research Clinic
Houston, Texas, 77008
Allegiant Clinical Research, LLC
Houston, Texas, 77024
MD
Houston, Texas, 77042
Todd J. Swick, MD, PA
Houston, Texas, 77063
Davis Clinic
Indianapolis, Indiana, 46260
Goldpoint Clinical Research
Indianapolis, Indiana, 46260
Eastside Therapeutic Resource
Kirkland, Washington, 98033
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, 89128
Premier Psychiatric Research Institute, LLC
Lincoln, Nebraska, 68510
Paul E. Wylie
Little Rock, Arkansas, 72211
Pacific Institute for Medical Research Inc
Los Angeles, California, 90024
MD
Lubbock, Texas, 79423
Florida Clinical Research Center LLC
Maitland, Florida, 32751
AMR Baber Research Inc.
Naperville, Illinois, 60563
Louisiana Research Associates, Inc.
New Orleans, Louisiana, 70114
Neurocare, Inc.
Newton, Massachusetts, 02459
American Medical Research, Inc.
Oak Brook, Illinois, 60523
Excell Research, Inc.
Oceanside, California, 92056
North County Clinical Research (NCCR)
Oceanside, California, 92056
IPS Reserach Company
Oklahoma City, Oklahoma, 73103
Pahl Pharmaceutical Professionals, LLC
Oklahoma City, Oklahoma, 73112
Cutting Edge Research Group
Oklahoma City, Oklahoma, 73116
Eminence Research, LLC
Oklahoma City, Oklahoma, 73139
Pacific Clinical Research Medical Group
Orange, California, 92868
SDS Clinical Trials
Orange, California, 92868
Aspen Clinical Research, LLC
Orem, Utah, 84058
Florida Institute for Clinical Research, LLC
Orlando, Florida, 32822
Psychiatric Associates
Overland Park, Kansas, 66211
Pedia Research LLC
Owensboro, Kentucky, 42301
California Clinical Trials Medical Group
Paramount, California, 90723
CRI Worldwide
Philadelphia, Pennsylvania, 19139
PsyPharma Clinical Research
Phoenix, Arizona, 85050
The Mech Center
Plano, Texas, 75024
Oregon Center for Clinical Investigations, Inc.
Portland, Oregon, 97210
Clinical Innovations, Inc.
Riverside, California, 92506
Midwest Research Group
Saint Charles, Missouri, 63301
Artemis Institute for Clinical Research
San Diego, California, 92123
Clinical Innovations, Inc.
San Diego, California, 92128
Neuropsychiatric Research Center of Orange County
Santa Ana, California, 92701
Clinical Innovations, Inc.
Santa Ana, California, 92705
SomnoMedics, LLC
Tampa, Florida, 33607
Pediatric Epilepsy and Neurology Specialists
Tampa, Florida, 33609
Clinical Neurophysiology Services, P.C.
Troy, Michigan, 48085
REM Medical Clinical Research
Tucson, Arizona, 85712
Tulsa Clinical Research
Tulsa, Oklahoma, 74104
Paradigm Research Professional, LLP
Tulsa, Oklahoma, 74114
Elite Clinical Trials
Wildomar, California, 92595
CRI Worldwide, LLC
Willingboro, New Jersey, 08046
About this study
Official title: A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Read the detailed description
This is a multi center, randomized, double blind, placebo controlled, fixed dose study of eszopiclone in pediatric subjects 6-17 years of age, inclusive, with ADHD associated insomnia. Subjects will be randomized at approximately 1:1:1 to either low dose oral eszopiclone (1 mg for children ages 6-11 years, 2 mg for adolescents ages 12-17 years), high dose oral eszopiclone (2 mg for children ages 6-11 years, 3 mg for adolescents ages 12-17 years) or placebo. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
- Conditions
- Insomnia, Attention Deficit Hyperactivity Disorder
- Being tested
- eszopiclone, Placebo
- Keywords
- Hypnotic, Eszopiclone, Attention Deficit/Hyperactivity Disorder, Insomnia, Children, Adolescent, Polysomnography, Actigraphy
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eszopicloneDrug
1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
eszopicloneDrug
2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
PlaceboDrug
1 tablet per day for 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Low dose eszopiclone | Experimental | 1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years Receives: Drug: eszopiclone |
| High dose eszopiclone | Experimental | 2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years Receives: Drug: eszopiclone |
| Placebo | Placebo comparator | Placebo 6-17 years Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).
A central scoring facility was used to derive the PSG sleep parameters Latency to Persistent Sleep (LPS) from the epochs and stages collected via the PSG recordings. Each epoch is 30 seconds. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Change from BL at Week 12 in LPS was derived from Week 12 LPS subtracted by BL LPS. Latency to persistent sleep (LPS; minutes): time from lights out to the first of 20 consecutive epochs (10 minutes) of non-wake, as determined by PSG recordings.
Measured: Baseline (Day 0) to Week 12
Secondary outcomes (19)
Change From Baseline (Day 0) to Week 12 in PSG Defined Wake Time After Sleep Onset (WASO)
A central scoring facility was used to derive the PSG sleep parameters Wake Time After Sleep Onset (WASO) from the epochs and stages collected via the PSG recordings. Each epoch is 30 seconds. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Change from BL at Week 12 in WASO was derived from Week 12 WASO subtracted by BL WASO. Wake time after sleep onset (WASO; minutes): The number of wake epochs after the onset of persistent sleep to the end of the recording, divided by 2.
Measured: Baseline (Day 0) to Week 12
Change From Baseline in Clinical Global Improvement (CGI)-Parent/Caregiver at Week 12
The CGI-I Parent/Caregiver was completed by the investigator based on interviews and interactions with the subject's parent or caregiver and represented their assessment of severity and improvement in the subject's symptoms since the start of the study. A 7 point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).
Measured: Baseline (Day 0) to Week 12
Change From Baseline in CGI-Child at Week 12
The CGI - I Child was completed by the investigator based on interviews and interactions with the subject and represented the subject's assessment of improvement in his/her symptoms since the start of the study. A 7 point scale was used for improvement with numeric values assigned to each of the responses: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), and very much worse (7).
Measured: Baseline (Day 0) to Week 12
Change From Baseline (Day 0) to Week 12 in Conners' ADHD Inattention Rating Scale.
The Conners' 3 -Parent Short Form was completed by the parent and provided an assessment of Attention-Deficit/ Hyperactivity Disorder (ADHD) and the most common comorbid problems and disorders in children and adolescents. It is a multi-informant assessment of children and adolescents between 6 and 18 years of age that took into account home, social and school settings. The short version of the Conners' 3 -Parent Short Form was a subset of items from the full-length form, and included the Conners' 3 Content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. The scale scores were presented as standardized age and gender based t scores. Inattention score was used for this endpoint. The lowest scale score is 40 (best) and the highest is 90 (worse)].
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective SL (Sleep Latency)
A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of SL over a pre-defined time period. SL is subjective time to fall asleep.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective Wake Time After Sleep Onset (WASO).
A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of WASO over a pre-defined time period. WASO is the aggregate duration of awakenings from the time subjects fall asleep until last awakening. Wake time after sleep onset (WASO; minutes): The number of wake epochs after the onset of persistent sleep to the end of the recording, divided by 2.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in PSG Defined Sleep Efficiency (SE)
A central scoring facility was used to derive the PSG sleep parameter of Sleep Efficiency (SE) from the epochs and stages collected via the PSG recordings. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Sleep efficiency: (total sleep time)/(total recording time) x 100. For this endpoint, total sleep time was defined as the number of non-wake epochs from the beginning of recording to the end of recording divided by 2. If total recording time was greater than 960 epochs (480 minutes), total sleep time was calculated from the PSG truncated at 480 minutes.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in PSG Defined Number of Awakenings After Sleep Onset (NAASO).
A central scoring facility was used to derive the PSG sleep parameter of Number of Awakenings after Sleep Onset (NAASO). The PSG parameters provided an objective assessment of the subject's sleep on a given night. Number of awakenings: The number of times, after onset of persistent sleep, that there was a wake entry of at least one-minute duration. Each awakening must have been separated by an epoch of non rapid eye movement (NREM) sleep stage 2, 3/4, or rapid eye movement (REM) sleep.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in PSG Defined Total Sleep Time (TST)
A central scoring facility was used to derive the PSG sleep parameter of Total Sleep Time (TST) from the epochs and stages collected via the PSG recordings. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Total sleep time was defined as the number of non-wake epochs from the beginning of recording to the end of recording divided by 2. If total recording time was greater than 960 epochs (480 minutes), total sleep time was calculated from the PSG truncated at 480 minutes.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective Total Sleep Time (TST).
A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of TST over a pre-defined time period. TST is subjective total sleep time.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 11 in Subjective Sleep Latency (SL) Measured by Actigraphy Monitoring in the Actigraphy Population.
A central scoring facility was used to derive the actigraphy sleep parameter of Sleep Latency (SL). Actigraphy data were used for additional efficacy evaluation as well as for the evaluation of rebound and withdrawal effects.
Measured: Baseline (Day 0) to Week 11
Change From Baseline to Week 11 in Subjective WASO From Actigraphy Population.
A central scoring facility was used to derive the actigraphy sleep parameters Wake Time After Sleep Onset (WASO). Actigraphy data were used for additional efficacy evaluation as well as for the evaluation of rebound and withdrawal effects.
Measured: Baseline (Day 0) to Week 11
Change From Baseline to Week 11 in Total Sleep Time (TST) Measured by Actigraphy Monitoring in the Actigraphy Population.
A central scoring facility was used to derive the actigraphy sleep parameter of Total Sleep Time (TST). Actigraphy data were used for additional efficacy evaluation as well as for the evaluation of rebound and withdrawal effects.
Measured: Baseline (Day 0) to Week 11
Change From Baseline to Week 12 in Pediatric Daytime Sleepiness Scale (PDSS) Total Score.
The PDSS is a validated measure of excessive sleepiness specifically designed for use in school aged children. The scale allowed for measurement of sleepiness across several relatively sedentary activities and provided a means to unmask sleepiness that may not be recognized during more active situations. It consisted of 8 items that assessed the frequency of a sleep related behavior (eg, how often do you fall asleep or get drowsy during class periods; are you usually alert most of the day; how often do you think you need more sleep) using a 5-point Likert type scale (0 = never, 4 = always). All items were summed to obtain the PDSS total score. PDSS data were used for efficacy evaluation as well as for the evaluation of residual effects.The overall PDSS scores range from a low of 0 where the individual is endorsing each item at the lowest level of sleepiness to a high of 32 where the individual is endorsing each item at the highest level of sleepiness.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Coding Copy Subtest / Digit Symbol Substitution Test (DSST) Scaled Score.
These tests are standardized information processing tasks to assess recognition and recoding of sensory information. The subject was given 90 seconds to complete as many substitutions of symbols as possible according to a code provided on top of the sheet. The Coding Copy Subtest A was used for subjects 6-7 years of age and the Coding Copy Subtest B was used for subjects 8-16 years of age, and the DSST was used for subjects 17 years of age. The score is the number of squares filled in correctly. Individuals are measured against their own pre-treatment baseline to determine levels of impairment using the scaled score. Higher scores mean less impairment (or potentially improvement) as the number of correct substitutions generally improves as cognition improves. Scaled scores are used to account for age differences among test takers. Scaled scores range from 1 to 19, and higher scores indicate higher cognitive function.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Pediatric Quality-of-Life Scale (Short Form-10).
The SF 10 Health Survey for Children is a 10 item care-giver completed assessment designed to measure children's health-related quality of life. The scale asked questions about the child's physical wellness, feelings, behavior, and activities at school and with family and friends. The SF 10 Physical and Psychosocial summary measures were scored such that higher scores indicated more favorable functioning.
Measured: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective Number of Awakenings After Sleep Onset (NAASO).
A Sponsor produced sleep questionnaire asked the subject or parent/guardian to report information about the subject's sleep and daytime functioning since the last visit. This questionnaire provided a subjective assessment of NAASO over a pre-defined time period.
Measured: Baseline (Day 0) to Week 12
Change in School Tardiness/Attendance Reports at Week 12 (Days)
School tardiness/attendance reports were to be collected when subject was actively enrolled in school (fall and spring semesters only; summer school, camps or other school attendance was not recorded.) The School Tardiness Report captured the number of days that the subject was tardy to school, had partial attendance at school or was completely absent from school. Data were collected for the 30-day period prior to Baseline, 6-week period prior to Week 6, 6-week period prior to Week 12.
Measured: Baseline (Day 0) to Week 12
Change in School Tardiness/Attendance Reports at Week 12 (Hours)
School tardiness/attendance reports were to be collected when subject was actively enrolled in school (fall and spring semesters only; summer school, camps or other school attendance was not recorded.) The School Tardiness Report captured the number of days that the subject was tardy to school, had partial attendance at school or was completely absent from school. Data were collected for the 30-day period prior to Baseline, 6-week period prior to Week 6, 6-week period prior to Week 12.
Measured: Baseline (Day 0) to Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2009 (estimated)
- Study startMay 2009
- Primary completionJul 2011
- Study completionJul 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for InsomniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 486 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00856973
- Sponsor's protocol ID
- 190-246
- Status last verified
- May 2013
- First submitted
- 4 Mar 2009
- Last updated
- 17 Jun 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014 Oct;134(4):e1095-103. doi: 10.1542/peds.2013-4221.
PubMed 25266438
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
- ClinicalTrials.gov ID
- NCT00856973
- Acronym / sponsor ID
- 190-246
- Conditions
- Insomnia, Attention Deficit Hyperactivity Disorder
- Keywords
- Hypnotic, Eszopiclone, Attention Deficit/Hyperactivity Disorder, Insomnia, Children, Adolescent, Polysomnography, Actigraphy
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 486 participants (actual)
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry (pharma, biotech, devices)
- Study start
- May 2009
- Primary completion
- Jul 2011 (actual)
- Study completion
- Jul 2011 (actual)
- First posted
- 6 Mar 2009 (estimated)
- Results
- Posted 10 Apr 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
Detailed description
This is a multi center, randomized, double blind, placebo controlled, fixed dose study of eszopiclone in pediatric subjects 6-17 years of age, inclusive, with ADHD associated insomnia. Subjects will be randomized at approximately 1:1:1 to either low dose oral eszopiclone (1 mg for children ages 6-11 years, 2 mg for adolescents ages 12-17 years), high dose oral eszopiclone (2 mg for children ages 6-11 years, 3 mg for adolescents ages 12-17 years) or placebo. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Low dose eszopiclone | Experimental | Drug: eszopiclone1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years |
| High dose eszopiclone | Experimental | Drug: eszopiclone2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo 6-17 years |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (10 listed)
- Subject is male or female 6 to 17 years of age, inclusive, at the time of consent.
- Subject must have a diagnosis of ADHD as defined by DSM-IV criteria
- Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation, (wake time after sleep onset >45 minutes) despite adequate age appropriate time and opportunity for sleep.
- Subject's Baseline PSG must reveal either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake after sleep onset (WASO).
- Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.
Key exclusion criteria (14 listed)
- Subject with weight <10th percentile for age and gender
- Subject has any clinically significant or unstable medical illness/abnormality or chronic disease.
- Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder or any history of psychosis.
- Subject has periodic limb movement >5 times per hour, as demonstrated on Baseline PSG.
- Subject has sleep disordered breathing, as demonstrated on Baseline PSG.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eszopiclone1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years | Drug | Low dose eszopiclone |
| eszopiclone2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years | Drug | High dose eszopiclone |
| Placebo1 tablet per day for 12 weeks | Drug | Placebo |
Primary outcome
Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).
Time frame: Baseline (Day 0) to Week 12
A central scoring facility was used to derive the PSG sleep parameters Latency to Persistent Sleep (LPS) from the epochs and stages collected via the PSG recordings. Each epoch is 30 seconds. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Change from BL at Week 12 in LPS was derived from Week 12 LPS subtracted by BL LPS. Latency to persistent sleep (LPS; minutes): time from lights out to the first of 20 consecutive epochs (10 minutes) of non-wake, as determined by PSG recordings.
19 secondary outcomes
Change From Baseline (Day 0) to Week 12 in PSG Defined Wake Time After Sleep Onset (WASO)
Time frame: Baseline (Day 0) to Week 12
Change From Baseline in Clinical Global Improvement (CGI)-Parent/Caregiver at Week 12
Time frame: Baseline (Day 0) to Week 12
Change From Baseline in CGI-Child at Week 12
Time frame: Baseline (Day 0) to Week 12
Change From Baseline (Day 0) to Week 12 in Conners' ADHD Inattention Rating Scale.
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective SL (Sleep Latency)
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective Wake Time After Sleep Onset (WASO).
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in PSG Defined Sleep Efficiency (SE)
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in PSG Defined Number of Awakenings After Sleep Onset (NAASO).
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in PSG Defined Total Sleep Time (TST)
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective Total Sleep Time (TST).
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 11 in Subjective Sleep Latency (SL) Measured by Actigraphy Monitoring in the Actigraphy Population.
Time frame: Baseline (Day 0) to Week 11
Change From Baseline to Week 11 in Subjective WASO From Actigraphy Population.
Time frame: Baseline (Day 0) to Week 11
Change From Baseline to Week 11 in Total Sleep Time (TST) Measured by Actigraphy Monitoring in the Actigraphy Population.
Time frame: Baseline (Day 0) to Week 11
Change From Baseline to Week 12 in Pediatric Daytime Sleepiness Scale (PDSS) Total Score.
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Coding Copy Subtest / Digit Symbol Substitution Test (DSST) Scaled Score.
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Pediatric Quality-of-Life Scale (Short Form-10).
Time frame: Baseline (Day 0) to Week 12
Change From Baseline to Week 12 in Subjective Number of Awakenings After Sleep Onset (NAASO).
Time frame: Baseline (Day 0) to Week 12
Change in School Tardiness/Attendance Reports at Week 12 (Days)
Time frame: Baseline (Day 0) to Week 12
Change in School Tardiness/Attendance Reports at Week 12 (Hours)
Time frame: Baseline (Day 0) to Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 25266438Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. Eszopiclone for insomnia associated with attention-deficit/hyperactivity disorder. Pediatrics. 2014 Oct;134(4):e1095-103. doi: 10.1542/peds.2013-4221.
Related trials for Insomnia
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Not yet recruiting
A Transdiagnostic Sleep Health Intervention for Veterans With PTSD
Stress Disorders, Post-Traumatic, Sleep Initiation and Maintenance Disorders
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)
Sleep Architecture, Mild Traumatic Brain Injury
RecruitingPhase 3
A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day
Insomia Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
73 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing eszopiclone in people with Insomnia and Attention Deficit Hyperactivity Disorder, run by Sumitomo Pharma America, Inc. at 73 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 73 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Apr 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS). (time frame: Baseline (Day 0) to Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00856973, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2013.